A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Conditions
Pancreatic Cancer · Metastatic Pancreatic Cancer · Metastatic Pancreatic Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton, Fullerton, California, United States
Hoag Mem Hosp Presbyterian, Newport Beach, California, United States
Baptist MD Anderson Cancer Institute, Jacksonville, Florida, United States
Saint Elizabeth Medical Center, Inc. DBA St. Elizabeth Health Care, Edgewood, Kentucky, United States
HealthPartners Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States
HealthPartners Cancer Center at Regions Hospital, Saint Paul, Minnesota, United States
NYU Long Island Mineola, Mineola, New York, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
White Plains Hospital Center for Cancer Care - Oncology, White Plains, New York, United States
UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
Utah Cancer Specialists, Salt Lake City, Utah, United States
UVA Emily Couric Cancer Center, Charlottesville, Virginia, United States
Virginia Cancer Specialists, Fairfax, Virginia, United States
Virginia Mason Franciscan Health - Virginia Mason Medical Center, Seattle, Washington, United States
Kyushu Group - Kyushu Cancer Center, Fukuoka, Fukuoka, Japan
The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
Yamaguchi University Hospital, Ube-shi, Yamaguchi, Japan
Study leads
Medical Director
Study Director
Astellas Pharma Global Development, Inc.